Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

OTLK Outlook Therapeutics, Inc.

Trading 07-30 10:51:48 EDT

0.9801

-0.0199

-1.99%

High1.03	Low0.9650	Vol4.27M
Open1.02	D1 Closing1.00	Amplitude6.50%
Mkt Cap183.28M	Tradable Cap158.00M	Total Shares187.00M
T/O4.25M	T/O Rate2.65%	Tradable Shares161.21M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"OTLK","market":"US","secType":"STK","nameCN":"Outlook Therapeutics, Inc.","latestPrice":0.9801,"timestamp":1785423105114,"preClose":1,"halted":0,"volume":4268195,"delay":0,"changeRate":-0.01990000000000003,"floatShares":161206747,"shares":187000000,"eps":-1.083111,"marketStatus":"Trading","change":-0.0199,"latestTime":"07-30 10:51:48 EDT","open":1.022,"high":1.03,"low":0.965,"amount":4250338.1525785,"amplitude":0.065,"askPrice":0.9808,"askSize":1000,"bidPrice":0.98,"bidSize":1100,"shortable":3,"etf":0,"ttmEps":-1.083111,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1785441600000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":1,"preHourTrading":{"tag":"盘前","latestPrice":1.02,"preClose":1,"latestTime":"09:29 EDT","volume":332745,"amount":346587.6245685,"timestamp":1785418196474,"change":0.02,"changeRate":0.02,"amplitude":0.08},"postHourTrading":{"tag":"盘后","latestPrice":1.0415,"preClose":1,"latestTime":"19:59 EDT","volume":679951,"amount":692078.3286,"timestamp":1785369581311,"change":0.0415,"changeRate":0.0415,"amplitude":0.0724},"volumeRatio":0.604938,"impliedVol":3.0597,"impliedVolPercentile":0.8725},"requestUrl":"/m/hq/s/OTLK/tweets","defaultTab":"tweets","newsList":[{"id":"2655813459","title":"Outlook Therapeutics Director Faisal Ghiath Sukhtian Acquires 95,398 Common Shares for $99,962.34","url":"https://stock-news.laohu8.com/highlight/detail?id=2655813459","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655813459?lang=en_us&edition=fundamental","pubTime":"2026-07-30 03:20","pubTimestamp":1785352823,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics director Faisal Ghiath Sukhtian acquires 95,398 common shares for $99,962.34Outlook Therapeutics director Sukhtian Faisal Ghiath bought 95,398 common shares at $1.05 per share.He ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nNDL4yQm:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Outlook Therapeutics Director Faisal Ghiath Sukhtian Acquires 95,398 Common Shares for $99,962.34","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654044715","title":"Analysts Offer Insights on Healthcare Companies: Outlook Therapeutics (OTLK) and Gossamer Bio (GOSS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2654044715","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654044715?lang=en_us&edition=fundamental","pubTime":"2026-07-28 01:10","pubTimestamp":1785172207,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Outlook Therapeutics (OTLK) and Gossamer Bio (GOSS). Outlook Ther...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-outlook-therapeutics-otlk-and-gossamer-bio-goss-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-outlook-therapeutics-otlk-and-gossamer-bio-goss-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","XBI","BK4581","LU0029874061.USD","BK4585","GOSS","BK4588","LU0128526141.USD","BK4137","BK4139","OTLK","BK4505","LABU","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654401978","title":"Outlook Therapeutics upgraded to Buy from Neutral at BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2654401978","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654401978?lang=en_us&edition=fundamental","pubTime":"2026-07-27 18:15","pubTimestamp":1785147354,"startTime":"0","endTime":"0","summary":"BTIG upgraded Outlook Therapeutics (OTLK) to Buy from Neutral with a $4 price target following FDA approval of LYTENAVA for wet AMD. Outlook Therap...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-upgraded-to-buy-from-neutral-at-btig-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-upgraded-to-buy-from-neutral-at-btig-thefly-news-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654199710","title":"Outlook Therapeutics Inc : Btig Raises to Buy from Neutral","url":"https://stock-news.laohu8.com/highlight/detail?id=2654199710","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654199710?lang=en_us&edition=fundamental","pubTime":"2026-07-27 18:15","pubTimestamp":1785147351,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nFWN43T0QY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654034821","title":"Outlook Therapeutics Gains Following FDA Approval of Macular-degeneration Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2654034821","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654034821?lang=en_us&edition=fundamental","pubTime":"2026-07-25 03:18","pubTimestamp":1784920680,"startTime":"0","endTime":"0","summary":"Shares of Outlook Therapeutics rose as the Food and Drug Administration approved the company's Lytenava for treatment of neovascular age-related macular degeneration.The stock was up 21%, to $1.60, late Friday. Shares hit a intraday high of $1.75 prior to a trading halt and pared some of the earlier gains once trading resumed.Outlook said it expects the drug to be available to eligible patients in the U.S. before year-end.Write to Josh Beckerman at josh.beckerman@wsj.com Dow Jones NewswiresJuly 24, 2026 15:18 ET Copyright  2026 Dow Jones & Company, Inc.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","BK4588","BK4139","BK4007","BK4539","OTLK","BK4585","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654031781","title":"NASDAQ Trade Halt Volatility Trading Pause at 03:00 Pm","url":"https://stock-news.laohu8.com/highlight/detail?id=2654031781","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654031781?lang=en_us&edition=fundamental","pubTime":"2026-07-25 03:00","pubTimestamp":1784919626,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTVOLATILITY TRADING PAUSE AT 03:00 PM","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nAQN2MBNB3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654303480","title":"Outlook jumps 24% to $1.64 after FDA approves wet AMD treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2654303480","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654303480?lang=en_us&edition=fundamental","pubTime":"2026-07-25 02:45","pubTimestamp":1784918711,"startTime":"0","endTime":"0","summary":"14:45 EDT Outlook jumps 24% to $1.64 after FDA approves wet AMD treatment Published first on TheFly – the ultimate source for real-time, market-mov...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/outlook-jumps-24-to-1-64-after-fda-approves-wet-amd-treatment-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/outlook-jumps-24-to-1-64-after-fda-approves-wet-amd-treatment-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654311520","title":"Outlook Therapeutics Announces Lytenava FDA Approval for Treatment of Wet AMD","url":"https://stock-news.laohu8.com/highlight/detail?id=2654311520","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654311520?lang=en_us&edition=fundamental","pubTime":"2026-07-25 02:43","pubTimestamp":1784918622,"startTime":"0","endTime":"0","summary":"BRIEF-Outlook Therapeutics Announces LYTENAVA FDA Approval For Treatment Of Wet AMDJuly 24 (Reuters)-Outlook Therapeutics IncOTLK.O:OUTLOOK THERAPEUTICS ANNOUNCES LYTENAVA FDA APPROVAL AS THE FIRST AN","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nTUAC9W73:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654903115","title":"US FDA Approves Outlook Therapeutics' Eye Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2654903115","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654903115?lang=en_us&edition=fundamental","pubTime":"2026-07-25 02:42","pubTimestamp":1784918531,"startTime":"0","endTime":"0","summary":"US FDA approves Outlook Therapeutics' eye disease drugJuly 24 (Reuters)-The U.S. Food and Drug Administration on Friday approved  Outlook Therapeutics'OTLK.Odrug for a type of eye disease that can cause severe vision loss, the company said.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nL4N43Q1J7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654900031","title":"Outlook Therapeutics Inc: Anticipated 12 Years of Market Exclusivity Under Biologics Price Competition and Innovation Act","url":"https://stock-news.laohu8.com/highlight/detail?id=2654900031","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654900031?lang=en_us&edition=fundamental","pubTime":"2026-07-25 02:40","pubTimestamp":1784918400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nTUAC9W73:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654803118","title":"Outlook Therapeutics - Lytenava Expected to be Available to U.S. Patients Before Year-end","url":"https://stock-news.laohu8.com/highlight/detail?id=2654803118","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654803118?lang=en_us&edition=fundamental","pubTime":"2026-07-25 02:40","pubTimestamp":1784918400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nTUAC9W73:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654031183","title":"Outlook Therapeutics Announces Lytenava™ FDA Approval as the First and Only Fda-approved Ophthalmic Bevacizumab for the Treatment of Wet Amd","url":"https://stock-news.laohu8.com/highlight/detail?id=2654031183","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654031183?lang=en_us&edition=fundamental","pubTime":"2026-07-25 02:40","pubTimestamp":1784918400,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nTUAC9W73:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654039485","title":"Outlook Therapeutics Inc trading halted, news pending","url":"https://stock-news.laohu8.com/highlight/detail?id=2654039485","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654039485?lang=en_us&edition=fundamental","pubTime":"2026-07-25 01:35","pubTimestamp":1784914511,"startTime":"0","endTime":"0","summary":"13:34 EDT Outlook Therapeutics (OTLK) Inc trading halted, news pending Published first on TheFly – the ultimate source for real-time, market-moving...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-inc-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/outlook-therapeutics-inc-trading-halted-news-pending-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4007","LENZ","OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654039137","title":"NASDAQ Trade Halt Halt News Pending at 01:34 Pm","url":"https://stock-news.laohu8.com/highlight/detail?id=2654039137","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654039137?lang=en_us&edition=fundamental","pubTime":"2026-07-25 01:34","pubTimestamp":1784914470,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTHALT NEWS PENDING AT 01:34 PM","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nAQN2MBMGX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653847085","title":"Outlook Therapeutics Grants CEO, CFO Options at $1.43 Per Share","url":"https://stock-news.laohu8.com/highlight/detail?id=2653847085","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653847085?lang=en_us&edition=fundamental","pubTime":"2026-07-24 18:03","pubTimestamp":1784887392,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics grants CEO, CFO options at $1.43 per shareOutlook Therapeutics set new executive compensation tied to a near-term FDA decision on ONS-5010 (bevacizumab-vikg).Granted stock options","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDL3F2tvr:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["OTLK","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652238890","title":"Outlook Therapeutics Registers 17.3 Million Shares for Resale","url":"https://stock-news.laohu8.com/highlight/detail?id=2652238890","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652238890?lang=en_us&edition=fundamental","pubTime":"2026-07-18 04:33","pubTimestamp":1784320384,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics  filed a prospectus Friday covering the potential resale of up to about 17.3 million shares of common stock issuable to selling stockholders upon exercise of warrants issued in connection with a securities offering that closed on April 23.The shares consist of roughly 16.1 million shares issuable upon exercise of common warrants and 1.1 million shares issuable upon exercise of placement agent warrants.Outlook Therapeutics said it will not receive proceeds from sales by the selling stockholders but will receive net proceeds from any warrants exercised for cash.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["OTLK","BK4007","LENZ","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2652256424","title":"Outlook Therapeutics Shareholders Approve Increase in Authorized Common Shares to 600 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2652256424","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652256424?lang=en_us&edition=fundamental","pubTime":"2026-07-17 04:09","pubTimestamp":1784232551,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics shareholders approve increase in authorized common shares to 600 millionOutlook Therapeutics shareholders met July 16, 2026, backing a charter amendment to raise authorized common","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260716:nNDL3zwT85:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OTLK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648256731","title":"Rocket Pharma Names Joseph Manhede Principal Accounting Officer, Effective July 8","url":"https://stock-news.laohu8.com/highlight/detail?id=2648256731","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648256731?lang=en_us&edition=fundamental","pubTime":"2026-07-01 05:16","pubTimestamp":1782854216,"startTime":"0","endTime":"0","summary":"Rocket Pharma names Joseph Manhede principal accounting officer, effective July 8Rocket Pharmaceuticals said VP of Finance, Senior Controller, Treasurer, Principal Accounting Officer John Militello wi","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL2l3GP3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AMRX","RCKT","OTLK","BK4007","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647468532","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Outlook Therapeutics (OTLK), Praxis Precision Medicines (PRAX) and Merck & Company (MRK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2647468532","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647468532?lang=en_us&edition=fundamental","pubTime":"2026-06-30 18:20","pubTimestamp":1782814820,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Outlook Therapeutics (OTLK), Praxis Precision Medicines (PRAX) an...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-outlook-therapeutics-otlk-praxis-precision-medicines-prax-and-merck-company-mrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-outlook-therapeutics-otlk-praxis-precision-medicines-prax-and-merck-company-mrk-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1037948897.HKD","LU0320765489.SGD","SG9999014559.SGD","LU1699723380.USD","IE00B2B36J28.USD","LU0211331839.USD","LU0965509283.SGD","LU1037948541.HKD","LU2361044865.SGD","LU1162221912.USD","IE00BBT3K403.USD","LU1057294990.SGD","LU0265550359.USD","LU0432979614.USD","LU0265550946.USD","LU2461242641.AUD","LU2491050154.USD","SG9999002232.USD","LU1941712348.USD","LU2433249047.HKD","IE00BN8TJ469.HKD","LU0130102774.USD","LU0266013472.USD","LU1093756168.USD","SG9999014575.USD","BK4533","LU0122379950.USD","LU1116320737.USD","LU2357627491.SGD","LU1974910355.USD","LU1934455863.HKD","LU2468319806.SGD","LU1116320901.HKD","LU0980610538.SGD","LU0203345920.USD","LU1023059063.AUD","LU0234572021.USD","LU1571399168.USD","LU0868494708.USD","LU1061106388.HKD","LU1983299246.USD","LU0965508806.USD","LU0058720904.USD","LU1989772840.SGD","LU0868494617.USD","LU2106854487.HKD","LU2360032135.SGD","BK4585","LU1941712264.USD","SG9999015358.SGD","SG9999001176.USD","LU0648001328.SGD","LU1201861249.SGD","BK4588","LU1585245621.USD","SG9999014542.SGD","IE00BLSP4452.SGD","SGXZ57979304.SGD","PRAX","LU2089984988.USD","OTLK","LU2324357040.USD","LU0861579265.USD","LU1093756325.SGD","IE00B1BXHZ80.USD","LU0106261372.USD","LU2491049909.HKD","LU1430594728.SGD","IE0002141913.USD","LU0889565916.HKD","BK4534","SG9999001176.SGD","IE00BFTCPJ56.SGD","LU2023250504.SGD","IE00BJT1NW94.SGD","LU1989772923.USD","BK4139","LU1066051225.USD","LU0098860793.USD","LU0320765992.SGD","LU2491050071.SGD","LU2125154935.USD","LU0477156953.USD","IE00BSNM7G36.USD","LU0006306889.USD","LU1066053197.SGD","SG9999002224.SGD","LU0109394709.USD","LU2125154778.USD","LU2125909593.SGD","BK4559","IE00BJJMRZ35.SGD","LU1066051811.HKD","LU1291159041.SGD","SG9999001440.SGD","SG9999013999.USD","LU0965509101.SGD","LU0130517989.USD","IE00B4R5TH58.HKD","LU0965509010.AUD","IE00BLSP4239.USD","LU2023250843.SGD","LU0208291251.USD","IE000M9KFDE8.USD","LU1035773651.USD","BK4550","LU1929549753.HKD","LU1934455194.USD","LU0859254822.USD","LU2112291526.USD","LU0070302665.USD","LU0238689110.USD","MRK","LU0985320562.USD","IE0009355771.USD","LU0320765646.SGD","LU1934455277.USD","SG9999015341.SGD","LU1917777945.USD","LU0942090050.USD","LU0203347892.USD","LU2125909247.SGD","LU2361044949.HKD","LU1069347547.HKD","LU2361045086.USD","LU0289739699.SGD","SG9999014567.USD","LU1989771016.USD","LU1923622614.USD","LU1066051498.USD","BK4516","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647770273","title":"Outlook Therapeutics Regains Nasdaq Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2647770273","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647770273?lang=en_us&edition=fundamental","pubTime":"2026-06-29 22:19","pubTimestamp":1782742749,"startTime":"0","endTime":"0","summary":"Outlook Therapeutics  said Friday it has regained compliance with Nasdaq's minimum bid price listing requirement.The company said it was notified that it had regained compliance as the closing bid price of its shares had been at $1 per share or greater for 10 consecutive business days.Shares of Outlook Therapeutics were 3.5% lower in Monday trading.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NQmain","LENZ","BK4139","BK4539","OTLK","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.outlooktherapeutics.com","stockEarnings":[{"period":"1week","weight":-0.2537},{"period":"1month","weight":-0.4083},{"period":"3month","weight":3},{"period":"6month","weight":1.2743},{"period":"1year","weight":-0.4924},{"period":"ytd","weight":-0.3671}],"compareEarnings":[{"period":"1week","weight":-0.024},{"period":"1month","weight":-0.0156},{"period":"3month","weight":0.015},{"period":"6month","weight":0.0542},{"period":"1year","weight":0.1483},{"period":"ytd","weight":0.0697}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.033268},{"month":2,"riseRate":0.4,"avgChangeRate":0.1402},{"month":3,"riseRate":0.3,"avgChangeRate":-0.095662},{"month":4,"riseRate":0.5,"avgChangeRate":-0.0707},{"month":5,"riseRate":0.7,"avgChangeRate":0.330761},{"month":6,"riseRate":0.4,"avgChangeRate":0.075556},{"month":7,"riseRate":0.545455,"avgChangeRate":0.004561},{"month":8,"riseRate":0.3,"avgChangeRate":-0.178581},{"month":9,"riseRate":0.5,"avgChangeRate":0.048784},{"month":10,"riseRate":0.5,"avgChangeRate":0.176993},{"month":11,"riseRate":0.2,"avgChangeRate":-0.102562},{"month":12,"riseRate":0.3,"avgChangeRate":-0.107149}],"exchange":"NASDAQ","name":"Outlook Therapeutics, Inc.","nameEN":"Outlook Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Outlook Therapeutics, Inc.,OTLK,Outlook Therapeutics, Inc.股票,Outlook Therapeutics, Inc.股票老虎,Outlook Therapeutics, Inc.股票老虎国际,Outlook Therapeutics, Inc.行情,Outlook Therapeutics, Inc.股票行情,Outlook Therapeutics, Inc.股价,Outlook Therapeutics, Inc.股市,Outlook Therapeutics, Inc.股票价格,Outlook Therapeutics, Inc.股票交易,Outlook Therapeutics, Inc.股票购买,Outlook Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Outlook Therapeutics, Inc.(OTLK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Outlook Therapeutics, Inc.(OTLK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction